Athlete Selective Androgen Receptor Modulators Abuse: A Systematic Review

被引:1
作者
Vasireddi, Nikhil [1 ,2 ]
Hahamyan, Henrik A. [3 ]
Gould, Heath P. [4 ]
Gregory, Andrew J. M. [5 ]
Gausden, Elizabeth B. [4 ]
Dodson, Christopher C. [6 ]
Voos, James E. [1 ,2 ]
Calcei, Jacob G. [1 ,2 ]
机构
[1] Case Western Reserve Univ, Sch Med, 10600 Chester Ave,Apartment 814, Cleveland, OH 44106 USA
[2] Univ Hosp Drusinsky Sports Med Inst, Cleveland, OH USA
[3] East Tennessee State Univ, Quillen Coll Med, Johnson City, TN USA
[4] Hosp Special Surg, New York, NY USA
[5] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[6] Rothman Inst, Philadelphia, PA USA
关键词
athletes; athletic injuries; doping in sports; drug abuse; selective androgen receptor modulators; sports medicine; PREVENTS BONE LOSS; DOPING AGENTS; PHYSICAL FUNCTION; S-4; ANDARINE; DOUBLE-BLIND; MUSCLE MASS; SUBSTANCES; ENOBOSARM; SARM; INFORMATION;
D O I
10.1177/03635465241252435
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Background: Selective androgen receptor modulators (SARMs) are small-molecule compounds that exert agonist and antagonist effects on androgen receptors in a tissue-specific fashion. Because of their performance-enhancing implications, SARMs are increasingly abused by athletes. To date, SARMs have no Food and Drug Administration approved use, and recent case reports associate the use of SARMs with deleterious effects such as drug-induced liver injury, myocarditis, and tendon rupture.Purpose: (1) To provide a comprehensive synthesis of the literature pertaining to SARMs from a sports medicine perspective and (2) to provide a better understanding of the clinical effects, treatment protocols, prevalence, and potential contamination associated with athlete-consumed SARMs.Study Design: Systematic review; Level of evidence, 4.Methods: A systematic review of the English-language literature from PubMed, Cochrane, and Embase databases was performed according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Articles relevant to SARM clinical outcomes, elimination profiles, contamination, safety profiles, prevalence, and doping control were included.Results: A total of 72 articles from 2003 to 2022 were identified for inclusion. The prevalence of SARM use among athletes is estimated to be 1% to 3%. SARM preclinical and clinical studies reported significant increases in lean body mass and side effects-including bone remodeling, testosterone suppression, and kidney, liver, and prostate enlargement. Thirteen case reports described 15 cases of SARM abuse. All described patients were men, with a median age of 32 years (range, 19-52 years), more than half were identified as athletes (8/15), and all ingested SARMs orally for a mean course of 8 weeks. Five patients described in the case reports explicitly denied "illicit drug use," implying patients may believe their use to be legal. Athletes most commonly purchased SARMs online, and most of these compounds have been shown to be contaminated with other substances, contributing to adverse effects. Athletes reported consuming SARMs at much higher doses than clinically studied, which may increase the risk of the reported side effects, such as liver injury, impaired insulin sensitivity, cardiovascular events, and tendon damage.Conclusion: The results of this systematic review serve to educate sports medicine clinicians and researchers on how to better identify, diagnose, and treat athlete SARM abuse. SARM use is associated with increased muscle mass, hepatotoxicity, cardiotoxicity, tendon damage, and androgenic side effects throughout the body-including prostate enlargement and serum testosterone suppression. Identifying and treating SARM abuse requires taking a thorough substance and supplement use history with open communication, providing literature-supported patient education, negotiating SARM discontinuation, and performing multidisciplinary treatment of adverse events. Athlete SARM abuse is increasingly widespread and unsafe, and public health oversight bodies should advocate for regulation of these gray-market compounds.
引用
收藏
页码:999 / 1009
页数:11
相关论文
共 100 条
[1]  
Ademiluyi G, 2003, PATIENT EDUC COUNS, V50, P151
[2]  
[Anonymous], 2019, 2018 anti-doping testing figures
[3]  
[Anonymous], 2016 anti-doping testing figures
[4]   Ligandrol (LGD-4033)-Induced Liver Injury [J].
Barbara, Mary ;
Dhingra, Sadhna ;
Mindikoglu, Ayse L. .
ACG CASE REPORTS JOURNAL, 2020, 7 (06)
[5]   The Safety, Pharmacokinetics, and Effects of LGD-4033, a Novel Nonsteroidal Oral, Selective Androgen Receptor Modulator, in Healthy Young Men [J].
Basaria, Shehzad ;
Collins, Lauren ;
Dillon, E. Lichar ;
Orwoll, Katie ;
Storer, Thomas W. ;
Miciek, Renee ;
Ulloor, Jagadish ;
Zhang, Anqi ;
Eder, Richard ;
Zientek, Heather ;
Gordon, Gilad ;
Kazmi, Syed ;
Sheffied-Moore, Melinda ;
Bhasin, Shalender .
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2013, 68 (01) :87-95
[6]   Drug-Induced Liver Injury From Enobosarm (Ostarine), a Selective Androgen Receptor Modulator [J].
Bedi, Harjot ;
Hammond, Carl ;
Sanders, David ;
Yang, Hui-Min ;
Yoshida, Eric M. .
ACG CASE REPORTS JOURNAL, 2021, 8 (01)
[7]   Selective androgen receptor modulators as function promoting therapies [J].
Bhasin, Shalender ;
Jasuja, Ravi .
CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, 2009, 12 (03) :232-240
[8]   LGD-4033 and MK-677 use impacts body composition, circulating biomarkers, and skeletal muscle androgenic hormone and receptor content: A case report [J].
Cardaci, Thomas D. ;
Machek, Steven B. ;
Wilburn, Dylan T. ;
Heileson, Jeffery L. ;
Harris, Dillon R. ;
Cintineo, Harry P. ;
Willoughby, Darryn S. .
EXPERIMENTAL PHYSIOLOGY, 2022, 107 (12) :1467-1476
[9]   Selective androgen receptor modulators: the future of androgen therapy? [J].
Christiansen, Andrew R. ;
Lipshultz, Larry I. ;
Hotaling, James M. ;
Pastuszak, Alexander W. .
TRANSLATIONAL ANDROLOGY AND UROLOGY, 2020, 9 :S135-S148
[10]   The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial [J].
Dalton, James T. ;
Barnette, Kester G. ;
Bohl, Casey E. ;
Hancock, Michael L. ;
Rodriguez, Domingo ;
Dodson, Shontelle T. ;
Morton, Ronald A. ;
Steiner, Mitchell S. .
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE, 2011, 2 (03) :153-161